Valuation: Xencor, Inc.

Market Cap 154.73Cr 133.84Cr 124.99Cr 114.66Cr 215.66Cr 15TCr 219.08Cr 1.47TCr 575.56Cr 7.38TCr 581.04Cr 568.32Cr 24TCr P/E 2026 *
-6.86x
P/E 2027 * -6.52x
Enterprise Value 111.43Cr 96Cr 90Cr 83Cr 155.31Cr 11TCr 157.77Cr 1.06TCr 414.5Cr 5.32TCr 418.44Cr 409.28Cr 18TCr EV / Sales 2026 *
7.43x
EV / Sales 2027 * 12.7x
Free-Float
98.78%
Yield 2026 *
-
Yield 2027 * -
1 day+4.05%
1 week+2.97%
Current month+2.97%
1 month+29.13%
3 months+61.82%
6 months+74.43%
Current year+35.92%
1 week 19.07
Extreme 19.07
21.96
1 month 14.38
Extreme 14.38
21.96
Current year 10.38
Extreme 10.375
21.96
1 year 6.92
Extreme 6.92
21.96
3 years 6.92
Extreme 6.92
27.24
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 01/02/2005
Director of Finance/CFO 48 09/04/2024
Chief Tech/Sci/R&D Officer 61 01/10/2006
Director TitleAgeSince
Director/Board Member 55 01/08/1997
Director/Board Member 58 25/07/2014
Director/Board Member 72 18/03/2015
Date Insider Type Main position Quantity % Market Cap.
16/06/26 Free

Director

30,906 0.0417%
23/01/26 Fiscal year

Chief Technology Officer

10,644 0.0149%
19/12/25 Fiscal year

Chief Technology Officer

2,32,723 0.3259%
Change 5-day change 1-year change 3-year change Capi.($)
+4.05%+2.97%+187.83%-9.84% 154.73Cr
+8.49%+20.55%+70.77%+103.07% 6.81TCr
-1.18%+4.43%+36.33%+65.03% 5.52TCr
-1.09%+32.96%+19.67%+509.20% 2.86TCr
+0.57%+18.87%+55.18%+5.18% 2.4TCr
+2.72%+3.41%-16.11%-12.04% 2.35TCr
-1.53%+6.34%+44.60%-23.74% 1.84TCr
-2.04%+10.84%+31.01%+628.97% 1.64TCr
-3.88%+16.98%+199.30%+350.94% 1.58TCr
+3.58%+1.96%+43.35%+162.22% 1.34TCr
Average +0.97%+10.81%+67.19%+177.90% 2.65TCr
Weighted average by Cap. +1.85%+13.04%+51.65%+160.85%

Financials

2026 *2027 *
Net sales 15Cr 13Cr 12Cr 11Cr 21Cr 1.43TCr 21Cr 142.08Cr 56Cr 715.12Cr 56Cr 55Cr 2.36TCr 12Cr 11Cr 9.83Cr 9.02Cr 17Cr 1.16TCr 17Cr 115.33Cr 45Cr 580.51Cr 46Cr 45Cr 1.92TCr
Net income -24Cr -21Cr -19Cr -18Cr -33Cr -2.26TCr -34Cr -225.24Cr -88Cr -1.13TCr -89Cr -87Cr -3.75TCr -28Cr -24Cr -23Cr -21Cr -39Cr -2.67TCr -40Cr -266.35Cr -104.54Cr -1.34TCr -105.53Cr -103.22Cr -4.43TCr
Net Debt -43Cr -37Cr -35Cr -32Cr -60Cr -4.12TCr -61Cr -410.37Cr -161.07Cr -2.07TCr -162.6Cr -159.04Cr -6.83TCr -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
07/26/07 $20.81 +4.05% 11,24,578
06/26/06 $20.00 +0.81% 9,96,659
05/26/05 $19.84 -0.40% 8,26,085
04/26/04 $19.92 +2.68% 7,60,790
03/26/03 $19.40 -4.01% 7,14,422
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
20.81USD
Average target price
29.00USD
Spread / Average Target
+39.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock